GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
IM-MV 20-002_000 Het Nederlands Kanker Instituut Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies 25-06-2020 Vergunning verleend
IM-MV 20-003_000 AMC Clinical studies with MB‐CART2019.1, a product consisting of ex‐vivo lentiviral transduced T‐cells using a replication‐deficient lentiviral vector 17-06-2020 Vergunning verleend
IM-MV 20-004_000 UMCG Clinical studies with MB-CART2019.1, a product consisting of ex-vivo lentiviral transduced T-cells using a replication-deficient lentiviral vector 17-07-2020 Vergunning verleend
IM-MV 20-005_000 Erasmus MC Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies 17-07-2020 Vergunning verleend
IM-MV 20-006_000 Erasmus MC Clinical studies with MB-CART2019.1, a product consisting of ex-vivo lentiviral transduced T-cells using a replication-deficient lentiviral vector 21-07-2020 Vergunning verleend
IM-MV 20-007_000 LUMC Clinical trials with Ad26COVS1 10-07-2020 Vergunning verleend
IM-MV 20-008_000 Universitair Medisch Centrum Utrecht Clinical trials with Ad26COVS1 10-07-2020 Vergunning verleend
IM-MV 20-009_000 CHDR Clinical trials with Ad26COVS1 10-07-2020 Vergunning verleend
IM-MV 20-011_000 Pharmaceutical Research Associates Group Clinical trials with Ad26COVS1 10-07-2020 Vergunning verleend